FDA Accelerated Approval in Oncology: A Strategic Guide for Biopharma
The development of oncology therapeutics is often marked by biological complexity and long timelines required to demonstrate definitive...
12
Feb
02
Feb
Rethinking the “Dark Side”: Interview with Dr. Scott Pruitt
For decades, a familiar phrase has echoed through academic hallways and hospital corridors whenever a physician-scientist announces a...
27
Jan
Cancer Vaccine CMC Strategy: FDA Expectations for Manufacturing and Regulatory Readiness
Cancer vaccine manufacturing companies engaging the FDA must demonstrate a clear, phase-appropriate CMC strategy that supports both clinical...
23
Jan
Cancer Vaccines in the Checkpoint Era: Neoantigens, mRNA, and Phase 3 Progress
Cancer vaccines have been pursued for decades, yet repeated late-stage disappointments led many to doubt whether therapeutic vaccination...
21
Jan
Who Is Arc Nouvel?
From Merck to Modern Oncology Drug Development: Insights from Eric Rubin, MD Arc Nouvel works with biotech and...
16
Jan
Why Cancer Drugs Fail FDA Approval: How Clinical Trial Teams Can Prevent Rejection Early
In oncology drug development, FDA rejection is often perceived as a late-stage failure, an FDA Complete Response Letter...
